ArticleFrontiers in oncology2025
Transcriptome sequencing revealed that lymph node metastasis of papillary thyroid microcarcinoma is associated with high THBS4 expression and PDGFRA+ cancer-associated fibroblasts.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical lymph node metastasis is a major factor influencing recurrence after surgery for papillary thyroid cancer. Molecular markers that can predict the presence of lymph node metastasis and assess the aggressiveness of papillary thyroid microcarcinoma (PTMC) remain poorly understood. The research question addressed whether specific genes, such as thrombospondin-4 (THBS4), could serve as predictive biomarkers for guiding surgical strategies, particularly in cases where current imaging modalities fail to detect LNM in the central region, and the decision for prophylactic central neck dissection remains controversial. Methods: Transcriptome sequencing was employed to screen for differentially expressed genes and perform enrichment analysis. The study defined two groups of PTMC patients: LNM(n=50) and NLNM(n=50). 10 samples from each group were used for transcriptome sequencing. The expression of THBS4 was evaluated in both groups. Additionally, the correlation between THBS4 expression and cancer-associated fibroblasts (CAFs), specifically the PDGFRA+ inflammatory CAFs, was investigated to understand the stromal regulatory protein's role in PTMC aggressiveness. Results: The analysis of sequencing data revealed that THBS4 expression was significantly higher in LNM PTMC compared to the NLNM group (Fold Change > 1.6 and P < 0.05). LNM PTMCs were also associated with a higher presence of PDGFRA+ inflammatory CAFs (P < 0.05), while no significant difference in the quantity of SMA+ myofibroblastic CAFs was observed between the two groups(P>0.05). Immunohistochemical analysis demonstrated increased THBS4(P < 0.01) and PDGFRA(P < 0.001) expression in LNM groups, while SMA staining showed no significant intergroup differences(P>0.05). Conclusion: This study's findings indicate that THBS4 could be a potential biomarker for predicting the risk of lymph node metastasis in papillary thyroid microcarcinoma, thus potentially guiding more personalized surgical interventions. Further validation in larger patient cohorts and the interactions between THBS4 and CAFs are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.